1. Additional file 1: Figure S1. of One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond
- Author
-
Dayon, Loïc, Seu Guiraud, Corthésy, John, Silva, Laeticia Da, Migliavacca, Eugenia, Domilė Tautvydaitė, Oikonomidi, Aikaterini, Moullet, Barbara, Henry, Hugues, Métairon, Sylviane, Marquis, Julien, Descombes, Patrick, Collino, Sebastiano, François-Pierre Martin, Montoliu, Ivan, Kussmann, Martin, Wojcik, Jérôme, Bowman, Gene, and Popp, Julius
- Subjects
mental disorders - Abstract
Box plots of CSF metabolite measurements for CDR of 0 and CDR >0 (i.e., CDR 0.5 or 1). Level of significance is indicated as p value after Bonferroni correction. Values were log-transformed. Figure S2. Box plots of plasma metabolite measurements for CDR 0 and CDR >0 (i.e., CDR 0.5 or 1). Level of significance is indicated as p value after Bonferroni correction. Concentration values were log-transformed. Figure S3. CSF and plasma metabolites correlated with CSF p-tau181 (a) and CSF tau (b) in APOE ε4 carriers (n = 37). Concentration values were log-transformed. Each dot represents a subject. The black line represents the linear fit, and the gray shading represents its confidence interval. Figure S4. Box plots of plasma metabolite measurements in APOE ε4 carriers (n = 37) according to CSF p-tau181/Aβ1–42 ratio (i.e., “low” when p-tau181/Aβ1–42 is ≤0.0779 and “high” when p-tau181/Aβ1–42 is > 0.0779) for negative and positive CSF profiles of AD pathology, respectively. Concentration values were log10-transformed. Level of significance is indicated as p value after Bonferroni correction. Supplementary Methods. (PDF 831 kb)
- Published
- 2017
- Full Text
- View/download PDF